ARWR Arrowhead Pharmaceuticals, Inc.
Healthcare$78.68+4.98%ClosedMarket Cap: $11.08B
As of 2026-05-26
Valuation
P/E (TTM)
45.10
PEG
0.34
P/B
17.39
P/S
16.97
EV/EBITDA
-87.32
DCF Value
$-97.97
FCF Yield
-0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-35.7%
Net Margin
-48.4%
ROE
-55.4%
ROA
-13.3%
ROIC
-11.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $73.7M | 100.0% | $-141.3M | $-132.7M | $— | — |
| Q1 null | $264.0M | 100.0% | $40.8M | $30.8M | $— | — |
| Q4 null | $256.5M | 100.0% | $44.1M | $-23.8M | $— | — |
| FY null | $829.4M | 100.0% | $98.3M | $-1.6M | $— | — |
| Q3 null | $27.8M | 100.0% | $-165.6M | $-175.2M | $— | — |
| Q2 null | $542.7M | 100.0% | $381.2M | $370.4M | $— | — |
| Q1 null | $2.5M | 100.0% | $-161.4M | $-173.1M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-162.2M | $-170.5M | $— | — |
| FY null | $3.6M | -423.7% | $-601.1M | $-599.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-176.1M | $-170.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-126.2M | $-125.3M | $— | — |
| Q1 2024 | $3.6M | -20.1% | $-136.5M | $-132.9M | $-1.24 | — |